AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Systemic Sclerosis

Recent research efforts aimed at curing Systemic Sclerosis.

Last updated

Systemic Sclerosis

Overview

Systemic sclerosis (SSc), also called systemic scleroderma, is a rare autoimmune disease in which abnormal immune activity, blood-vessel injury, and overactive fibroblasts—the cells that make connective tissue—cause excessive collagen and scarring. It can tighten skin and damage the lungs, heart, kidneys, digestive tract, and circulation; diffuse cutaneous SSc generally has more rapid skin progression and greater internal-organ risk than limited cutaneous disease. NIAMS overview (niams.nih.gov)

It affects women more often than men and commonly begins in adulthood. Prognosis varies greatly according to organ involvement, especially interstitial lung disease (ILD), pulmonary arterial hypertension, heart disease, and renal crisis. There is no validated cure: current care combines monitoring at expert centers with treatments targeted to the affected organs, including immune-suppressing medicines such as mycophenolate or cyclophosphamide, anti-fibrotic treatment for progressive SSc-ILD, vasodilators for vascular complications, and symptom-directed gastrointestinal and rehabilitation care. NIAMS diagnosis and treatment EULAR recommendations (niams.nih.gov)

Scope of Recent Research (2020–present)

Research activity has accelerated substantially since 2020, with the dominant questions shifting from how to slow fibrosis to whether the abnormal immune system can be deeply “reset” before permanent organ damage occurs. The most cure-oriented approaches are high-intensity immune ablation followed by autologous hematopoietic stem-cell transplantation (AHSCT) and engineered cell therapies that remove CD19-positive B cells; meanwhile, anti-fibrotic and targeted immune drugs aim to preserve organ function rather than eliminate the disease mechanism. The field has produced striking early remissions, but no approach has yet shown the large, long-term, controlled evidence needed to call it a cure. EULAR recommendations CASTLE CAR-T trial (ard.bmj.com)

Major Breakthroughs and Emerging Therapies

The best-established immune-reset strategy is AHSCT. Doctors collect a person’s own blood-forming stem cells, use intensive immune-suppressing treatment to remove much of the existing immune system, then return the stored cells to rebuild it. Long-term follow-up of the French ASTIS cohort found better composite outcomes, skin improvement, and disability scores with non-myeloablative AHSCT than with cyclophosphamide in carefully selected people with severe SSc. French ASTIS long-term outcomes (pubmed.ncbi.nlm.nih.gov) A 2026 phase 2 study at University Hospital Tübingen tested an organ-adapted transplant-conditioning regimen for patients with cardiac and/or lung involvement who would have been excluded from earlier trials; the regimen was feasible, but its 11% treatment-related mortality within 100 days demonstrates why transplantation remains a specialized, high-risk intervention rather than a routine cure. Adapted AHSCT phase 2 trial (sciencedirect.com)

B-cell-directed treatment has strengthened the case that B cells help drive SSc. In the randomized DESIRES trial, rituximab—an antibody that depletes CD20-positive B cells—improved skin thickening at 24 weeks compared with placebo in 56 participants. It is an important disease-modifying signal, but rituximab does not eliminate long-lived antibody-producing plasma cells and has not established durable, treatment-free remission. DESIRES rituximab trial (pubmed.ncbi.nlm.nih.gov)

The most consequential emerging strategy is CD19 chimeric antigen receptor T-cell (CAR-T) therapy. This treatment collects a person’s T cells, engineers them to recognize CD19 on B cells, and reinfuses them after temporary lymphocyte-lowering chemotherapy. In a 2025 Erlangen case series of six people with severe diffuse SSc, no predefined progression or treatment-intensification events occurred over a median 487 days; median skin-score improvement was 31% within 100 days, while lung ground-glass abnormalities and forced vital capacity also improved or stabilized. Erlangen CD19 CAR-T case series (sciencedirect.com)

The larger phase 1/2a CASTLE basket trial subsequently reported outcomes across refractory lupus, SSc, and inflammatory myositis. All SSc participants met the study’s CRISS-50 composite-response threshold, and the entire 24-person cohort remained free of immunosuppressants and glucocorticoids without relapse during a median 13 months of follow-up. The study also documented a biologic “reset”: after B cells returned, naïve B cells predominated and memory B-cell and plasmablast populations were greatly reduced. These results are highly encouraging, but they remain early, uncontrolled evidence in selected patients with relatively short follow-up. CASTLE CAR-T trial (nature.com)

Researchers are also pursuing potentially more scalable engineered-cell platforms. A 2025 first-in-human report described QN-139b, an induced-pluripotent-stem-cell-derived, gene-edited, dual CD19/BCMA-targeting CAR natural-killer-cell product in a patient with refractory SSc. Targeting both CD19-positive B cells and BCMA-positive plasma-cell populations could produce a deeper immune reset, while an “off-the-shelf” donor-derived product could avoid individualized manufacturing; however, this remains a single-patient experimental report, not proof of safety, durability, or cure. Dual-target iPSC CAR-NK report (sciencedirect.com)

Clinical Trials and Experimental Approaches

AHSCT remains under active refinement. The multicenter UPSIDE trial compared upfront AHSCT with initial cyclophosphamide followed by mycophenolate, reserving transplant for treatment failure, in early diffuse cutaneous SSc. The registry listed the trial as completed as of March 24, 2026, but no results had been posted, making its eventual comparative results an important near-term milestone. UPSIDE trial record (clinicaltrials.gov)

Cell-therapy development is now broader than the initial academic CAR-T studies. Cabaletta Bio’s open-label phase 1/2 RESET-SSc study is testing autologous CD19 CAR-T therapy, rese-cel/CABA-201, in adults with treatment-refractory SSc; participants receive cyclophosphamide and fludarabine preconditioning before one infusion and require prolonged follow-up. RESET-SSc at Duke (dukehealth.org) Kyverna’s CARTIMMUNE study includes diffuse cutaneous SSc among several severe autoimmune diseases treated with KYV-101, another autologous anti-CD19 CAR-T product. CARTIMMUNE trial (clinicaltrials.gov)

An alternative is donor-derived CAR natural-killer therapy, designed to be manufactured in advance rather than separately for each patient. Nkarta’s Ntrust-2 is a phase 1/2 basket study of the allogeneic CD19 CAR-NK product NKX019 in SSc and other immune-mediated diseases; it measures safety as well as skin score, SSc composite response, ILD progression, autoantibodies, and patient-reported gastrointestinal outcomes. Ntrust-2 NKX019 trial (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers are combining clinical outcome measures with biological evidence of disease reversal. Trials track skin fibrosis using the modified Rodnan Skin Score, lung disease using pulmonary-function tests and high-resolution CT, and multisystem response using the ACR/EULAR Composite Response Index in Systemic Sclerosis (CRISS). CAR-T studies additionally measure CAR-cell expansion, B-cell depletion and reconstitution, autoantibody levels, immunoglobulins, infection risk, and the proportions of naïve versus memory B cells to determine whether a true immune reset has occurred. CASTLE CAR-T trial (nature.com)

At the tissue level, investigators use skin biopsies, single-cell RNA sequencing, and spatial transcriptomics—methods that show which genes are active in individual cells while retaining their positions in tissue—to identify pathogenic fibroblast subtypes and their interactions with immune cells. A 2025 spatial-transcriptomic study identified COL8A1-positive fibroblasts and their immune niches as candidate indicators of progressive skin fibrosis, offering potential biomarkers for selecting patients and measuring response earlier in future cure trials. Spatial fibroblast phenotyping (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Major clinical and translational centers include University Hospital Erlangen, which led the early CD19 CAR-T SSc studies; University Hospital Tübingen, which is refining transplant conditioning; UMC Utrecht, sponsor of UPSIDE; and Duke University, a RESET-SSc site. Industry programs from Cabaletta Bio, Kyverna Therapeutics, and Nkarta are now testing autologous CAR-T and allogeneic CAR-NK platforms in formal clinical studies. Erlangen CD19 CAR-T case series Adapted AHSCT phase 2 trial UPSIDE trial record RESET-SSc at Duke Ntrust-2 NKX019 trial (sciencedirect.com)

In the United States, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a dedicated Scleroderma, Fibrosis, and Autoinflammatory Disease Program within its extramural research portfolio. NIAMS grants and programs (niams.nih.gov) The Scleroderma Research Foundation funds investigator grants, the U.S. CONQUER longitudinal registry, the genetics-focused GRASP collaboration, and the international CONQUEST phase 2 platform trial in SSc-ILD. SRF research program (srfcure.org) The National Scleroderma Foundation reports current annual research investment exceeding $1.5 million and awarded $1.6 million for treatment-and-cure research in its 2023 grant cycle. National Scleroderma Foundation grants 2023 NSF research awards (scleroderma.org)

Strengths, Limitations, and Challenges

The key strength of the current wave of research is that immune-reset therapies are producing improvements across skin, lungs, symptoms, function, and medication-free disease control—outcomes not easily explained by treating a single symptom alone. CAR-T may be less toxic in autoimmune disease than in cancer because lower cell doses can be used, and CASTLE reported no high-grade cytokine-release syndrome, no neurotoxicity, and no major hematologic toxicity. CASTLE CAR-T trial (nature.com)

The limitations are equally important. CAR-T evidence in SSc still comes from small, non-randomized cohorts with follow-up measured in months to a few years; it remains unknown how often disease will recur after B cells return, whether established fibrosis can reverse, and which patients will benefit without unacceptable risk. Lymphodepleting chemotherapy, infections, prolonged low blood counts, low antibody levels, cytokine-release syndrome, neurotoxicity, infertility risk, specialized-center requirements, and very high cost may all limit access. AHSCT has stronger comparative evidence but carries substantial early mortality risk and excludes many people with advanced heart or lung disease. Adapted AHSCT phase 2 trial CASTLE CAR-T trial (sciencedirect.com)

Outlook and Future Directions

As of August 8, 2026, systemic sclerosis is not close to having a universally applicable cure, but it is closer than it was in 2020 to therapies that may induce durable, drug-free remission in a subset of people with severe early disease. The decisive next milestones are publication of UPSIDE’s randomized transplant results; larger controlled CAR-T trials with multi-year follow-up; confirmation that immune reset prevents lung, heart, and kidney progression; and development of safer, less expensive off-the-shelf cell products. Until then, “cure” should be reserved for sustained remission with preserved organ function after treatment ends—not short-term improvement in a small uncontrolled study. UPSIDE trial record CASTLE CAR-T trial Ntrust-2 NKX019 trial (clinicaltrials.gov)

References

Don't see your disease? Request a report